PMID- 31214624
OWN - NLM
STAT- MEDLINE
DCOM- 20191206
LR  - 20200225
IS  - 2314-7156 (Electronic)
IS  - 2314-8861 (Print)
IS  - 2314-7156 (Linking)
VI  - 2019
DP  - 2019
TI  - Anti-inflammatory Property of Galectin-1 in a Murine Model of Allergic Airway 
      Inflammation.
PG  - 9705327
LID - 10.1155/2019/9705327 [doi]
LID - 9705327
AB  - Galectin-1 (Gal-1) has immunomodulatory activities in various allergic 
      inflammatory disorders, but its potential anti-inflammatory properties on 
      allergic airway diseases have not been confirmed. We explored the pharmacological 
      effects of Gal-1 on the progression of allergic airway inflammation and 
      investigated the underlying mechanism. Female C57BL/6 mice were sensitized on day 
      0 and challenged with ovalbumin (OVA) on days 14-17 to establish an allergic 
      airway inflammation model. In the challenge phase, a subset of mice was treated 
      intraperitoneally with recombinant Gal-1 (rGal-1) or dexamethasone (Dex). We 
      found that rGal-1 inhibited pulmonary inflammatory cell recruitment, mucus 
      secretion, bronchoalveolar lavage fluid (BALF) inflammatory cell infiltration, 
      and cytokine production. The treatment also suppressed the infiltration of 
      eosinophils into the allergic lung as indicated by decreased expression levels of 
      eotaxin and eosinophil peroxidase (EPX). However, only the expression levels of 
      IL-25, neither IL-33 nor TSLP, were significantly decreased in the lung by rGal-1 
      treatment. These immunomodulatory effects in the allergic lung were correlated 
      with the activation of extracellular signal-regulated kinase (ERK) signaling 
      pathway and downregulation of endogenous Gal-1. In addition, rGal-1 reduced the 
      plasma concentrations of anti-OVA immunoglobulin E (IgE) and IL-17. Our findings 
      suggest that rGal-1 is an effective therapy for allergic airway inflammation in a 
      murine model and may be a potential pharmacological target for allergic airway 
      inflammatory diseases.
FAU - Lv, Yunxiang
AU  - Lv Y
AD  - Department of Pulmonary Medicine, Anhui Geriatric Institute, The First Affiliated 
      Hospital of Anhui Medical University, Jixi Road 218, Hefei, Anhui 230022, China.
FAU - Dai, Mengyuan
AU  - Dai M
AD  - Department of Pulmonary Medicine, Anhui Geriatric Institute, The First Affiliated 
      Hospital of Anhui Medical University, Jixi Road 218, Hefei, Anhui 230022, China.
FAU - Wang, Muzi
AU  - Wang M
AD  - Department of Pulmonary Medicine, Anhui Geriatric Institute, The First Affiliated 
      Hospital of Anhui Medical University, Jixi Road 218, Hefei, Anhui 230022, China.
FAU - Chen, Fangfang
AU  - Chen F
AD  - Department of Pulmonary Medicine, Anhui Geriatric Institute, The First Affiliated 
      Hospital of Anhui Medical University, Jixi Road 218, Hefei, Anhui 230022, China.
FAU - Liu, Rongyu
AU  - Liu R
AUID- ORCID: 0000-0002-3601-9155
AD  - Department of Pulmonary Medicine, Anhui Geriatric Institute, The First Affiliated 
      Hospital of Anhui Medical University, Jixi Road 218, Hefei, Anhui 230022, China.
LA  - eng
PT  - Journal Article
DEP - 20190512
PL  - Egypt
TA  - J Immunol Res
JT  - Journal of immunology research
JID - 101627166
RN  - 0 (Allergens)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Cytokines)
RN  - 0 (Galectin 1)
RN  - 0 (Inflammation Mediators)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Allergens/immunology
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology
MH  - Bronchial Hyperreactivity/drug therapy/*immunology/metabolism/pathology
MH  - Bronchoalveolar Lavage Fluid/immunology
MH  - Cytokines/genetics/metabolism
MH  - Disease Models, Animal
MH  - Eosinophils/immunology/metabolism/pathology
MH  - Female
MH  - Galectin 1/*pharmacology
MH  - Gene Expression
MH  - Immunoglobulin E/blood/immunology
MH  - Immunohistochemistry
MH  - Inflammation Mediators/metabolism
MH  - Lung/drug effects/immunology/metabolism/pathology
MH  - MAP Kinase Signaling System
MH  - Mice
PMC - PMC6535876
EDAT- 2019/06/20 06:00
MHDA- 2019/12/18 06:00
PMCR- 2019/05/12
CRDT- 2019/06/20 06:00
PHST- 2018/11/19 00:00 [received]
PHST- 2019/03/02 00:00 [revised]
PHST- 2019/03/19 00:00 [accepted]
PHST- 2019/06/20 06:00 [entrez]
PHST- 2019/06/20 06:00 [pubmed]
PHST- 2019/12/18 06:00 [medline]
PHST- 2019/05/12 00:00 [pmc-release]
AID - 10.1155/2019/9705327 [doi]
PST - epublish
SO  - J Immunol Res. 2019 May 12;2019:9705327. doi: 10.1155/2019/9705327. eCollection 
      2019.